Nuwellis (NUWE) Company Report

Nuwellis, Inc. announced a private placement and warrant inducement transaction, anticipated to generate approximately $5.0 million in gross proceeds, with an expected closing date around January 30, 2026.
The private placement includes the sale of 994,537 shares of common stock (or pre-funded warrants) and warrants to purchase 1,989,074 shares, priced at a combined effective offering price of $3.09 per unit.
Concurrently, an investor will immediately exercise 623,585 existing warrants at a reduced price of $3.09, and in return, Nuwellis will issue 1,247,170 new warrants with an exercise price of $2.84 per share.
As of January 29, 2026, the company had 1,686,892 shares of common stock issued and outstanding.

8 days ago

Nuwellis Announces Private Placement and Warrant Inducement Transaction

NUWE

Nuwellis, Inc. has entered into a private placement and a warrant inducement transaction, which are expected to generate approximately $5.0 million in gross proceeds.
The private placement involves the sale of 994,537 shares of common stock (or pre-funded warrants) and warrants to purchase 1,989,074 shares, with a combined effective offering price of $3.09 per share/warrant.
Concurrently, an investor will immediately exercise existing warrants to purchase 623,585 shares at a reduced exercise price of $3.09, and will receive new warrants to purchase an additional 1,247,170 shares.
Both transactions are anticipated to close on or about January 30, 2026.

Jan 29, 2026, 9:36 PM

Nuwellis to acquire Rendiatech

NUWE

M&A

New Projects/Investments

Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., an Israeli medical technology company focused on automated kidney function monitoring.
This acquisition is a strategic expansion for Nuwellis, moving its portfolio beyond therapeutic fluid management into real-time renal diagnostics.
Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement.
Nuwellis intends to leverage its existing commercial infrastructure to integrate and develop Rendiatech's technology, aiming for future expansion into advanced urine-based analytics.

Jan 29, 2026, 9:35 PM

Nuwellis Announces Changes to Board of Directors

NUWE

Board Change

On January 21, 2026, Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the Board of Directors of Nuwellis, Inc., which subsequently reduced the board size from six to five members.
Katharyn Field and Mika Grasso were appointed to the Board, effective January 21, 2026.
The continued service of Ms. Field and Mr. Grasso on the Board is conditional on an equity investment of at least $5 million in the company being made within thirty days of the Form S-1 registration statement filing (or clearing SEC comments).

Jan 23, 2026, 10:02 PM

Nuwellis Reports Third Quarter 2025 Results

NUWE

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

Nuwellis, Inc. reported total revenue of $2.2 million for the third quarter of 2025, representing a 6% decrease year-over-year but a 29% increase sequentially.
The company's gross margin was 65.2%, and operating expenses rose 30% year-over-year to $4.1 million, leading to an operating loss of $2.7 million for the quarter.
Nuwellis ended Q3 2025 with $3.1 million in cash and cash equivalents and remains debt-free, having raised $1.9 million through an ATM facility during the quarter.
Key operational advancements include the U.S. launch of a new 24-hour circuit and dual-lumen extended-length catheter, the first Aquadex® therapies delivered in a hospital-based outpatient setting, and the initiation of an exit from international operations to concentrate on U.S. market growth.

Nov 12, 2025, 4:49 PM

Nuwellis Reports Third Quarter 2025 Results

NUWE

Earnings

Product Launch

New Projects/Investments

Nuwellis reported total revenue of $2.2 million for the third quarter ended September 30, 2025, representing a 6% decrease year-over-year but a 29% sequential increase. On a pro-forma basis, revenue grew approximately 7% year-over-year.
The company achieved year-over-year growth in circuit sales across all customer categories and launched a new 24-hour circuit and dual-lumen extended-length catheter in the U.S..
Nuwellis initiated an exit of international operations to focus on U.S. market growth and began a manufacturing transition to KDI Precision Manufacturing.
Gross margin for the quarter was 65.2%, with an operating loss of $2.7 million. The company ended the quarter with $3.1 million in cash and cash equivalents and remains debt-free, having raised $1.9 million through an ATM facility.

Nov 12, 2025, 1:15 PM

Nuwellis, Inc. Enters At The Market Offering Agreement

NUWE

On September 3, 2025, Nuwellis, Inc. entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc..
This agreement allows the company to sell shares of its common stock from time to time, with an initial aggregate offering price of up to $4,650,000.
Ladenburg Thalmann & Co. Inc. will serve as the sales agent and receive a commission of up to 3.0% of the gross proceeds from any sales.
Nuwellis, Inc. is not obligated to make any sales under this agreement.